A Randomised, Double Blind (Sponsor Unblinded), Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a IV Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2019
Price : $35 *
At a glance
- Drugs GSK 2831781 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 11 Jun 2018 Status changed from active, no longer recruiting to completed.
- 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.